|
1
|
Shen Y, Zou L, Zeng Y, Xia T, Liu Z, Hu K,
Wang L and Feng J: Potential of Alkaloids from Zanthoxylum nitidum
var. tomentosum in treating rat rheumatoid arthritis model and
validation of molecular mechanisms. Curr Issues Mol Biol.
47:6612025. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu L, Wang J, Chen Y, Fang Y, Wang Z, Liu
X, Hong L, Tao Q and Xu Y: Efficacy and safety of the bushen quhan
zhiwang decoction to achieve clinical deep remission in rheumatoid
arthritis: Protocol for a double-blind, randomized,
placebo-controlled trial. J Pain Res. 18:4237–4249. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang Z, Dong Q, Zhang L, Wang X, Jiao Y,
Geng Q, Cai W, Zhang Q, Xiao C, Tao Q and Xu Y: Fibroblast
activation protein-α drives rheumatoid arthritis inflammation
through the AKT/mTOR signaling pathway and its therapeutic effect
by Wangbi granules. Phytomedicine. 147:1571792025. View Article : Google Scholar
|
|
4
|
Peng Z, Huang W, Tang M, Chen B, Yang R,
Liu Q, Liu C and Long P: Investigating the shared genetic
architecture between hypothyroidism and rheumatoid arthritis. Front
Immunol. 14:12864912024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen Y, Deng Y, Zheng H, Li B, Yang Y,
Huang J, Yuan H, Wang M, Wang W and Yu H: Xuetongsu attenuates
synovial inflammation in rheumatoid arthritis by inhibiting the
IL-23/IL-17/NF-κB inflammatory axis. Front Pharmacol.
16:16155192025. View Article : Google Scholar
|
|
6
|
Zhang Z, Liu L, Ti H, Chen M, Chen Y, Du
D, Zhan W, Wang T, Wu X, Wu J, et al: Synovial fibroblast derived
small extracellular vesicles miRNA15-29148 promotes articular
chondrocyte apoptosis in rheumatoid arthritis. Bone Res. 13:612025.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yuan FL, Li X, Lu WG, Li CW, Xu RS and
Dong J: IL-33: A promising therapeutic target for rheumatoid
arthritis? Expert Opin Ther Targets. 15:529–534. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yuan FL, Hu W, Lu WG, Li X, Li JP, Xu RS,
Li CW, Chen FH and Jin C: Targeting interleukin-21 in rheumatoid
arthritis. Mol Biol Rep. 38:1717–1721. 2011. View Article : Google Scholar
|
|
9
|
Firestein GS: Evolving concepts of
rheumatoid arthritis. Nature. 423:356–361. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ngo ST, Steyn FJ and McCombe PA: Gender
differences in autoimmune disease. Front Neuroendocrinol.
35:347–369. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hajar H and Lahcen A: insufficiency
fracture in a patient with rheumatoid arthritis in remission
receiving long-term methotrexate without conventional risk factors:
A case report and literature review. Cureus.
18:e1078062026.PubMed/NCBI
|
|
12
|
Hirose H, Higuchi T, Ichimura Y, Katsumata
Y, Tanaka E, Yamamoto T, Koenuma N, Yano K, Shinohara A, Seo S and
Harigai M: Periarticular other iatrogenic
immunodeficiency-associated lymphoproliferative disorder mimicking
knee synovitis in a patient with rheumatoid arthritis. Intern Med.
65:905–910. 2026. View Article : Google Scholar :
|
|
13
|
Ji L, Kong R, Yu Y, Wan W, Zhao D and Gao
J: Klotho promotes bone formation in rheumatoid
arthritis-associated osteoporosis by modulating the
Fgf23/Fgfr1/NF-κB pathway and inhibiting ferroptosis. Mol Immunol.
184:64–75. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Meng X, Chen Z, Li T, Nie Z, Han H, Zhong
S, Yin Z, Sun S, Xie J, Shen J, et al: Role and therapeutic
potential for targeting fibroblast growth factor 10/FGFR1 in
relapsed rheumatoid arthritis. Arthritis Rheumatol. 76:32–47. 2024.
View Article : Google Scholar
|
|
15
|
Etori K, Tanaka S, Tamura J, Hattori K,
Kagami SI, Nakamura J, Ohtori S and Nakajima H: Fibroblast growth
factor receptor 1 as a potential marker of terminal effector
peripheral T helper cells in rheumatoid arthritis patients.
Rheumatology (Oxford). 62:3763–3769. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Plotnikov AN, Schlessinger J, Hubbard SR
and Mohammadi M: Structural basis for FGF receptor dimerization and
activation. Cell. 98:641–650. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li X, Ellman MB, Kroin JS, Chen D, Yan D,
Mikecz K, Ranjan KC, Xiao G, Stein GS, Kim SG, et al:
Species-specific biological effects of FGF-2 in articular
cartilage: Implication for distinct roles within the FGF receptor
family. J Cell Biochem. 113:2532–2542. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu L, Leijten J, van Blitterswijk CA and
Karperien M: Fibroblast growth factor-1 is a mesenchymal stromal
cell-secreted factor stimulating proliferation of osteoarthritic
chondrocytes in co-culture. Stem Cells Dev. 22:2356–2367. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao S, Wang Y, Hou L, Wang Y, Xu N and
Zhang N: Pentraxin 3 inhibits fibroblast growth factor 2 induced
osteoclastogenesis in rheumatoid arthritis. Biomed Pharmacother.
131:1106282020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang ZZ, Liu F, Gong YF, Huang TY, Zhang
XM and Huang XY: Antiarthritic effects of sorafenib in rats with
adjuvant-induced arthritis. Anat Rec (Hoboken). 301:1519–1526.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Demuynck B, Shah BP, Mayeux F, Vasseur L,
Barbault F, Ding J, Paull M, Reddi T, Muslimova E and Legeai-Mallet
L: Infigratinib low dose therapy is an effective strategy to treat
hypochondroplasia. J Bone Miner Res. 40:1255–1264. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Othman AA, Babcock HE, Gill CS, Fraser JL,
Regier DS, Kaur R, Simpson KL and Ferreira CR: New Phenotypic
features in FGFR1-Related osteoglophonic dysplasia. Am J Med Genet
A. 197:e640922025. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Savarirayan R, De Bergua JM, Arundel P,
Salles JP, Saraff V, Delgado B, Leiva-Gea A, McDevitt H, Nicolino
M, Rossi M, et al: Oral infigratinib therapy in children with
achondroplasia. N Engl J Med. 392:865–874. 2025. View Article : Google Scholar
|
|
24
|
Rikimaru S, Nakao-Kuroishi K,
Kometani-Gunjigake K, Mizuhara M, Nakatomi C, Toyono T, Ono K and
Kawamoto T: Fibroblast growth factor 2 stimulates differentiation
of mechanically-stressed human periodontal ligament fibroblasts
into cementoblasts. Am J Orthod Dentofacial Orthop. 168:477–488.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yi X, Zimath PL, Martin-Vazquez E,
Oliveira JG, Jawurek S, Title AC, Yesildag B, Mourad NI, Buemi A,
Pattou F, et al: Transcriptomics of autoimmune diseases identifies
FGFR1 as a target for pancreatic β-cell protection. J Autoimmun.
156:1034692025. View Article : Google Scholar
|
|
26
|
Zhou H, Pan H, Li X, Huang L, Zhang R, Yan
X and Xu J: Ginsenoside reprogramming microglia through the
FGF/FGFR1 inhibits post traumatic stress disorder. Int
Immunopharmacol. 145:1137632025. View Article : Google Scholar
|
|
27
|
Li HZ, Zhang JL, Yuan DL, Xie WQ, Ladel
CH, Mobasheri A and Li YS: Role of signaling pathways in
age-related orthopedic diseases: Focus on the fibroblast growth
factor family. Mil Med Res. 11:402024.PubMed/NCBI
|
|
28
|
Demuynck B, Flipo J, Kaci N, Dambkowski C,
Paull M, Muslimova E, Shah BP and Legeai-Mallet L: Low-dose
infigratinib increases bone growth and corrects growth plate
abnormalities in an achondroplasia mouse model. J Bone Miner Res.
39:765–774. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dutra EH, Chen PJ, Kalajzic Z, Wadhwa S,
Hurley M and Yadav S: FGF ligands and receptors in osteochondral
tissues of the temporomandibular joint in young and aging mice.
Cartilage. 15:195–199. 2024. View Article : Google Scholar :
|
|
30
|
Wang Q, Li H, Mao Y, Garg A, Park ES, Wu
Y, Chow A, Peregrin J and Zhang X: Shc1 cooperates with Frs2 and
Shp2 to recruit Grb2 in FGF-induced lens development. Elife.
13:RP1036152025. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Q, Tao C, Wu Y, Anderson KE, Makrides
N, Hannan A, Peregrin J, Lin CS, Ding Z, Li W, et al: FGF-induced
phospholipase Cγ signaling regulates lacrimal gland branching by
competing with PI3K in phosphoinositide metabolism. Cell Rep.
44:1160462025. View Article : Google Scholar
|
|
32
|
Nakano K, Okada Y, Saito K and Tanaka Y:
Induction of RANKL expression and osteoclast maturation by the
binding of fibroblast growth factor 2 to heparan sulfate
proteoglycan on rheumatoid synovial fibroblasts. Arthritis Rheum.
50:2450–2458. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Soutto M, Zhang X, Bhat N, Chen Z, Zhu S,
Maacha S, Genoula M, El-Gazzaz O, Peng D, Lu H, et al: Fibroblast
growth factor receptor-4 mediates activation of nuclear factor
erythroid 2-Related Factor-2 in gastric tumorigenesis. Redox Biol.
69:1029982024. View Article : Google Scholar :
|
|
34
|
Farrell B and Breeze AL: Structure,
activation and dysregulation of fibroblast growth factor receptor
kinases: Perspectives for clinical targeting. Biochem Soc Trans.
46:1753–1770. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tang Y, Yang P, Jin M, Huang S, Chen H,
Chen L, Yang J and Su N: Fgfr1 deficiency in osteocytes leads to
increased bone mass by enhancing Wnt/β-catenin signaling. Bone.
174:1168172023. View Article : Google Scholar
|
|
36
|
Wang L, Luo W, Zhang S, Zhang J, He L, Shi
Y, Gao L, Wu B, Nie X, Hu C, et al: Macrophage-derived FGFR1 drives
atherosclerosis through PLCγ-mediated activation of NF-κB
inflammatory signalling pathway. Cardiovasc Res. 120:1385–1399.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kalinina J, Dutta K, Ilghari D, Beenken A,
Goetz R, Eliseenkova AV, Cowburn D and Mohammadi M: The
alternatively spliced acid box region plays a key role in FGF
receptor autoinhibition. Structure. 20:77–88. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ornitz DM and Itoh N: The fibroblast
growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol.
4:215–266. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schlessinger J, Plotnikov AN, Ibrahimi OA,
Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ and Mohammadi M:
Crystal structure of a ternary FGF-FGFR-heparin complex reveals a
dual role for heparin in FGFR binding and dimerization. Mol Cell.
6:743–750. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Farooq M, Khan AW, Kim MS and Choi S: The
role of fibroblast growth factor (FGF) signaling in tissue repair
and regeneration. Cells. 10:32422021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Orr-Urtreger A, Bedford MT, Burakova T,
Arman E, Zimmer Y, Yayon A, Givol D and Lonai P: Developmental
localization of the splicing alternatives of fibroblast growth
factor receptor-2 (FGFR2). Dev Biol. 158:475–486. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xu X, Weinstein M, Li C, Naski M, Cohen
RI, Ornitz DM, Leder P and Deng C: Fibroblast growth factor
receptor 2 (FGFR2)-mediated reciprocal regulation loop between FGF8
and FGF10 is essential for limb induction. Development.
125:753–765. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jin C, Wang F, Wu X, Yu C, Luo Y and
McKeehan WL: Directionally specific paracrine communication
mediated by epithelial FGF9 to stromal FGFR3 in two-compartment
premalignant prostate tumors. Cancer Res. 64:4555–4562. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yeh BK, Igarashi M, Eliseenkova AV,
Plotnikov AN, Sher I, Ron D, Aaronson SA and Mohammadi M:
Structural basis by which alternative splicing confers specificity
in fibroblast growth factor receptors. Proc Natl Acad Sci USA.
100:2266–2271. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Olsen SK, Li JY, Bromleigh C, Eliseenkova
AV, Ibrahimi OA, Lao Z, Zhang F, Linhardt RJ, Joyner AL and
Mohammadi M: Structural basis by which alternative splicing
modulates the organizer activity of FGF8 in the brain. Genes Dev.
20:185–198. 2006. View Article : Google Scholar :
|
|
46
|
Wiedemann M and Trueb B: Characterization
of a novel protein (FGFRL1) from human cartilage related to FGF
receptors. Genomics. 69:275–279. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Goida J and Pilmane M: The evaluation of
FGFR1, FGFR2 and FOXO1 in orofacial cleft tissue. Children (Basel).
9:5162022.PubMed/NCBI
|
|
48
|
Liu Q, Huang J, Yan W, Liu Z, Liu S and
Fang W: FGFR families: Biological functions and therapeutic
interventions in tumors. MedComm (2020). 4:e3672023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Trueb B, Amann R and Gerber SD: Role of
FGFRL1 and other FGF signaling proteins in early kidney
development. Cell Mol Life Sci. 70:2505–2518. 2013. View Article : Google Scholar
|
|
50
|
Steinberg F, Zhuang L, Beyeler M, Kälin
RE, Mullis PE, Brändli AW and Trueb B: The FGFRL1 receptor is shed
from cell membranes, binds fibroblast growth factors (FGFs), and
antagonizes FGF signaling in Xenopus embryos. J Biol Chem.
285:2193–2202. 2010. View Article : Google Scholar
|
|
51
|
Salmaso N, Stevens HE, McNeill J, ElSayed
M, Ren Q, Maragnoli ME, Schwartz ML, Tomasi S, Sapolsky RM, Duman R
and Vaccarino FM: Fibroblast growth factor 2 modulates hypothalamic
pituitary axis activity and anxiety behavior through glucocorticoid
receptors. Biol Psychiatry. 80:479–489. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Regeenes R, Silva PN, Chang HH, Arany EJ,
Shukalyuk AI, Audet J, Kilkenny DM and Rocheleau JV: Fibroblast
growth factor receptor 5 (FGFR5) is a co-receptor for FGFR1 that is
up-regulated in beta-cells by cytokine-induced inflammation. J Biol
Chem. 293:17218–17228. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Pal V, Wang Y, Regeenes R, Kilkenny DM and
Rocheleau JV: Laminin matrix regulates beta-cell FGFR5 expression
to enhance glucose-stimulated metabolism. Sci Rep. 12:61102022.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kähkönen TE, Ivaska KK, Jiang M, Büki KG,
Väänänen HK and Härkönen PL: Role of fibroblast growth factor
receptors (FGFR) and FGFR like-1 (FGFRL1) in mesenchymal stromal
cell differentiation to osteoblasts and adipocytes. Mol Cell
Endocrinol. 461:194–204. 2018. View Article : Google Scholar
|
|
55
|
Silva PN, Altamentova SM, Kilkenny DM and
Rocheleau JV: Fibroblast growth factor receptor like-1 (FGFRL1)
interacts with SHP-1 phosphatase at insulin secretory granules and
induces beta-cell ERK1/2 protein activation. J Biol Chem.
288:17859–17870. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Han X, Yang J, Li L, Huang J, King G and
Quarles LD: Conditional deletion of Fgfr1 in the proximal and
distal tubule identifies distinct roles in phosphate and calcium
transport. PLoS One. 11:e01478452016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Xu Z, Luo W, Chen L, Zhuang Z, Yang D,
Qian J, Khan ZA, Guan X, Wang Y, Li X and Liang G: Ang II
(Angiotensin II)-Induced FGFR1 (Fibroblast Growth Factor Receptor
1) activation in tubular epithelial cells promotes hypertensive
kidney fibrosis and injury. Hypertension. 79:2028–2041. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Pepe F, Russo G, Scimone C, Palumbo L,
Tommasi S, Pinto R, De Biase D, Maloberti T, Busico A, Santoro A,
et al: Harmonization trial of FGFR1-3 testing strategies in
cholangiocarcinoma patients: An Italian multicenter experience.
Pathologica. 117:496–507. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Cheng YM, Chou CY, Hsu YC and Chen MJ:
Influence of HPV16 E6/7 on the expression of FGF2 and FGFR type B
in cervical carcinogenesis. Reprod Sci. 19:580–586. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Muh SJ, Hovhannisyan RH and Carstens RP: A
Non-sequence-specific double-stranded RNA structural element
regulates splicing of two mutually exclusive exons of fibroblast
growth factor receptor 2 (FGFR2). J Biol Chem. 277:50143–50154.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Shin JW, Min M, Larrieu-Lahargue F, Canron
X, Kunstfeld R, Nguyen L, Henderson JE, Bikfalvi A, Detmar M and
Hong YK: Prox1 promotes lineage-specific expression of fibroblast
growth factor (FGF) receptor-3 in lymphatic endothelium: A role for
FGF signaling in lymphangiogenesis. Mol Biol Cell. 17:576–584.
2006. View Article : Google Scholar :
|
|
62
|
Shimokawa K, Kimura-Yoshida C, Nagai N,
Mukai K, Matsubara K, Watanabe H, Matsuda Y, Mochida K and Matsuo
I: Cell surface heparan sulfate chains regulate local reception of
FGF signaling in the mouse embryo. Dev Cell. 21:257–272. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Xu D and Esko JD: Demystifying heparan
sulfate-protein interactions. Annu Rev Biochem. 83:129–157. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Belov AA and Mohammadi M: Molecular
mechanisms of fibroblast growth factor signaling in physiology and
pathology. Cold Spring Harb Perspect Biol. 5:a0159582013.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wu ZL, Zhang L, Yabe T, Kuberan B, Beeler
DL, Love A and Rosenberg RD: The involvement of heparan sulfate
(HS) in FGF1/HS/FGFR1 signaling complex. J Biol Chem.
278:17121–17129. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kuro-o M: Endocrine FGFs and Klothos:
Emerging concepts. Trends Endocrinol Metab. 19:239–245. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Urakawa I, Yamazaki Y, Shimada T, Iijima
K, Hasegawa H, Okawa K, Fujita T, Fukumoto S and Yamashita T:
Klotho converts canonical FGF receptor into a specific receptor for
FGF23. Nature. 444:770–774. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M,
Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW and
Kuro-o M: Regulation of fibroblast growth factor-23 signaling by
klotho. J Biol Chem. 281:6120–6123. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Goetz R and Mohammadi M: Exploring
mechanisms of FGF signalling through the lens of structural
biology. Nat Rev Mol Cell Biol. 14:166–180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Furdui CM, Lew ED, Schlessinger J and
Anderson KS: Autophosphorylation of FGFR1 kinase is mediated by a
sequential and precisely ordered reaction. Mol Cell. 21:711–717.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Sahni M, Ambrosetti DC, Mansukhani A,
Gertner R, Levy D and Basilico C: FGF signaling inhibits
chondrocyte proliferation and regulates bone development through
the STAT-1 pathway. Genes Dev. 13:1361–1366. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Su WC, Kitagawa M, Xue N, Xie B, Garofalo
S, Cho J, Deng C, Horton WA and Fu XY: Activation of Stat1 by
mutant fibroblast growth-factor receptor in thanatophoric dysplasia
type II dwarfism. Nature. 386:288–292. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Lamothe B, Yamada M, Schaeper U,
Birchmeier W, Lax I and Schlessinger J: The docking protein Gab1 is
an essential component of an indirect mechanism for fibroblast
growth factor stimulation of the phosphatidylinositol 3-kinase/Akt
antiapoptotic pathway. Mol Cell Biol. 24:5657–5666. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Kouhara H, Hadari YR, Spivak-Kroizman T,
Schilling J, Bar-Sagi D, Lax I and Schlessinger J: A lipid-anchored
Grb2-binding protein that links FGF-receptor activation to the
Ras/MAPK signaling pathway. Cell. 89:693–702. 1997. View Article : Google Scholar
|
|
75
|
Kanazawa S, Fujiwara T, Matsuzaki S,
Shingaki K, Taniguchi M, Miyata S, Tohyama M, Sakai Y, Yano K,
Hosokawa K and Kubo T: bFGF regulates PI3-kinase-Rac1-JNK pathway
and promotes fibroblast migration in wound healing. PLoS One.
5:e122282010. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Liao S, Porter D, Scott A, Newman G,
Doetschman T and Schultz Jel J: The cardioprotective effect of the
low molecular weight isoform of fibroblast growth factor-2: the
role of JNK signaling. J Mol Cell Cardiol. 42:106–120. 2007.
View Article : Google Scholar
|
|
77
|
House SL, Branch K, Newman G, Doetschman T
and Schultz Jel J: Cardioprotection induced by cardiac-specific
overexpression of fibroblast growth factor-2 is mediated by the
MAPK cascade. Am J Physiol Heart Circ Physiol. 289:H2167–H2175.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Tsang M and Dawid IB: Promotion and
attenuation of FGF signaling through the Ras-MAPK pathway. Sci
STKE. 2004:pe172004. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Tan Y, Rouse J, Zhang A, Cariati S, Cohen
P and Comb MJ: FGF and stress regulate CREB and ATF-1 via a pathway
involving p38 MAP kinase and MAPKAP kinase-2. EMBO J. 15:4629–4642.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Moon AM, Guris DL, Seo JH, Li L, Hammond
J, Talbot A and Imamoto A: Crkl deficiency disrupts Fgf8 signaling
in a mouse model of 22q11 deletion syndromes. Dev Cell. 10:71–80.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Bogale DE: The roles of FGFR3 and c-MYC in
urothelial bladder cancer. Discov Oncol. 15:2952024. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Timsah Z, Ahmed Z, Lin CC, Melo FA, Stagg
LJ, Leonard PG, Jeyabal P, Berrout J, O'Neil RG, Bogdanov M and
Ladbury JE: Competition between Grb2 and Plcγ1 for FGFR2 regulates
basal phospholipase activity and invasion. Nat Struct Mol Biol.
21:180–188. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Hanafusa H, Torii S, Yasunaga T and
Nishida E: Sprouty1 and Sprouty2 provide a control mechanism for
the Ras/MAPK signalling pathway. Nat Cell Biol. 4:850–858. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Torii S, Kusakabe M, Yamamoto T, Maekawa M
and Nishida E: Sef is a spatial regulator for Ras/MAP kinase
signaling. Dev Cell. 7:33–44. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Camps M, Nichols A, Gillieron C, Antonsson
B, Muda M, Chabert C, Boschert U and Arkinstall S: Catalytic
activation of the phosphatase MKP-3 by ERK2 mitogen-activated
protein kinase. Science. 280:1262–1265. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Wong A, Lamothe B, Lee A, Schlessinger J
and Lax I: FRS2 alpha attenuates FGF receptor signaling by
Grb2-mediated recruitment of the ubiquitin ligase Cbl. Proc Natl
Acad Sci USA. 99:6684–6689. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Dufour C, Guenou H, Kaabeche K, Bouvard D,
Sanjay A and Marie PJ: FGFR2-Cbl interaction in lipid rafts
triggers attenuation of PI3K/Akt signaling and osteoblast survival.
Bone. 42:1032–1039. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Browaeys-Poly E, Blanquart C, Perdereau D,
Antoine AF, Goenaga D, Luzy JP, Chen H, Garbay C, Issad T, Cailliau
K and Burnol AF: Grb14 inhibits FGF receptor signaling through the
regulation of PLCγ recruitment and activation. FEBS Lett.
584:4383–4388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Huang SW, Yu HC, Huang HB, Chen PC and Lu
MC: Inhibiting pyruvate carboxylase as a potential therapeutic
strategy for alleviating rheumatoid arthritis.
Inflammopharmacology. 34:4239–4252. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Morice A, de La Seiglière A, Kany A,
Khonsari RH, Bensidhoum M, Puig-Lombardi ME and Legeai Mallet L:
FGFR antagonists restore defective mandibular bone repair in a
mouse model of osteochondrodysplasia. Bone Res. 13:122025.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Liao S, Li J, Gao S, Han Y, Han X, Wu Y,
Bi J, Xu M and Bi W: Sulfatinib, a novel multi-targeted tyrosine
kinase inhibitor of FGFR1, CSF1R, and VEGFR1-3, suppresses
osteosarcoma proliferation and invasion via dual role in tumor
cells and tumor microenvironment. Front Oncol. 13:11588572023.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Wehrli M, Oppliger Leibundgut E, Gattiker
HH, Manz MG, Müller AM and Goede JS: Response to tyrosine kinase
inhibitors in myeloproliferative neoplasia with 8p11 translocation
and CEP110-FGFR1 rearrangement. Oncologist. 22:480–483. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Peng H, Myers J, Fang X, Stachowiak EK,
Maher PA, Martins GG, Popescu G, Berezney R and Stachowiak MK:
Integrative nuclear FGFR1 signaling (INFS) pathway mediates
activation of the tyrosine hydroxylase gene by angiotensin II,
depolarization and protein kinase C. J Neurochem. 81:506–524. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Sait SF, Bale T and Karajannis MA: FGFR
alterations and potential role of FGFR inhibitors in pediatric
brain tumors. Neurooncol Adv. 8(Suppl 2): ii31–ii40. 2025.
|
|
95
|
Pichler R, van Creij NCH, Mertens LS, Del
Giudice F, Koll F, Soria F, Subiela JD, Plage H, Tymoszuk P, Mayr
R, et al: FGFR1/3 signaling as an achilles' heel of phenotypic
diversity in urothelial carcinoma. Eur Urol Oncol. 9:220–226. 2026.
View Article : Google Scholar
|
|
96
|
Lu X, Chen H, Patterson AV, Smaill JB and
Ding K: Fibroblast growth factor receptor 4 (FGFR4) selective
inhibitors as hepatocellular carcinoma therapy: Advances and
prospects. J Med Chem. 62:2905–2915. 2019. View Article : Google Scholar
|
|
97
|
Katoh M: FGFR inhibitors: Effects on
cancer cells, tumor microenvironment and whole-body homeostasis
(Review). Int J Mol Med. 38:3–15. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Suzuki Y, Shimizu H, Ishizuka N, Kubota N,
Kubota T, Senoo A, Kageyama H, Osaka T, Hirako S, Kim HJ, et al:
Vagal hyperactivity due to ventromedial hypothalamic lesions
increases adiponectin production and release. Diabetes.
63:1637–1648. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Abdel-Mohsen HT, Ibrahim MA, Nageeb AM and
El Kerdawy AM: Receptor-based pharmacophore modeling, molecular
docking, synthesis and biological evaluation of novel VEGFR-2,
FGFR-1, and BRAF multi-kinase inhibitors. BMC Chem. 18:422024.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Roskoski R Jr: The role of fibroblast
growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in
the treatment of cancers including those of the urinary bladder.
Pharmacol Res. 151:1045672020. View Article : Google Scholar
|
|
101
|
Yoon GH, Park DS, Kim MS and Choi SC:
Perillic acid disrupts the specification of germ layers by
upregulating the FGF/MAPK pathway. Genes Genomics. 47:637–649.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Orsmond A, Krishnan G, Palmer LJ, De Sousa
SMC and McCormack A: FGFR1 variation in the divergent settings of
congenital hypopituitarism and pituitary tumours. Pituitary.
28:392025. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Clark JF and Soriano P: Diverse Fgfr1
signaling pathways and endocytic trafficking regulate mesoderm
development. Genes Dev. 38:393–414. 2024.PubMed/NCBI
|
|
104
|
Thisse B and Thisse C: Functions and
regulations of fibroblast growth factor signaling during embryonic
development. Dev Biol. 287:390–402. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Lu W, Jiang M, Zhuang J, Song J, Zhou C,
Zhou Y, Zhu Z, Wu A, Sheng S, Zhu S and Wang Z: FGF4 activates
FGFR1 - PI3K/AKT signaling to enhance Clec10a-mediated
intracellular myelin debris processing and promote spinal cord
repair. J Neuroinflammation. 23:1072026. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Yang X, Li X, Zhang X, Meng L, Wang J and
Zheng N: Comparative evaluation of the short-chain fatty acids
formate, propionate, and valerate on intestinal barrier maturation
and bone development in neonatal mice. Food Funct. 17:3372–3385.
2026. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Sawano K, Nagasaki K, Suzuki E, Ogiwara Y,
Kageyama I, Fukami M and Kuroki Y: De novo retrotransposon
insertion into the FGFR1 gene in a boy with congenital
hypogonadotropic hypogonadism: A case report. Front Endocrinol
(Lausanne). 16:15653162025. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Tuokkola JE and Schwertfeger KL: Breast
cancer progression by the FGF/FGFR axis: A metabolic perspective. J
Mammary Gland Biol Neoplasia. 31:22025. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Wu AL, Kolumam G, Stawicki S, Chen Y, Li
J, Zavala-Solorio J, Phamluong K, Feng B, Li L, Marsters S, et al:
Amelioration of type 2 diabetes by antibody-mediated activation of
fibroblast growth factor receptor 1. Sci Transl Med. 3:113ra262011.
View Article : Google Scholar
|
|
110
|
Stamou MI, Chiu CJ, Jadhav SV, Lopes VF,
Salnikov KB, Plummer L, Lippincott MF, Lee H, Seminara SB and
Balasubramanian R: Defective FGFR1 signaling disrupts glucose
regulation: Evidence from humans with FGFR1 mutations. J Endocr
Soc. 8:bvae1182024. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Seki D and Honda M: FGF-2-Overexpressing
adipose-derived stem cells as a paracrine platform for
angiogenesis-driven tissue regeneration. Cell Mol Bioeng. 19:73–87.
2026. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Feng Y, Chen B, Xu Y, Xu X, Hu B, Li T,
Zhang D, Bai B, Liu C, Xu W, et al: Multifunctional bioactive
scaffold facilitating BMSCs-Driven osteogenesis and vascularization
in critical-sized bone defect repair. Adv Sci (Weinh).
13:e226922026. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Dong Q, Tao J, Yuan J, Tian J, Cheng Y,
Wang J, Xiao C, Chen X, Wang Y, Li W and Shen F: FGF20 activates
FGFR1-PI3K-AKT signaling to coordinate barrier integrity and
alveolar coagulation in sepsis-induced lung injury. Cell Signal.
145:1125742026. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Seitz T and Hellerbrand C: Role of
fibroblast growth factor signalling in hepatic fibrosis. Liver Int.
41:1201–1215. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Kim S, An S, Lee J, Jeong Y, You CL, Kim
H, Bae JH, Yun CE, Ryu D, Bae GU and Kang JS: Cdon ablation in
motor neurons causes age-related motor neuron degeneration and
impaired sciatic nerve repair. J Cachexia Sarcopenia Muscle.
14:2239–2252. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Meng J, Lv Z, Chen X, Sun C, Jin C, Ding K
and Chen C: LBP1C-2 from Lycium barbarum maintains skeletal muscle
satellite cell pool by interaction with FGFR1. iScience.
26:1065732023. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Farooq M, Hwang M, Khan AW, Batool M,
Ahmad B, Kim W, Kim MS and Choi S: Identification of a novel
fibroblast growth factor receptor-agonistic peptide and its effect
on diabetic wound healing. Life Sci. 364:1234322025. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Lee SB, Abdal Dayem A, Kmiecik S, Lim KM,
Seo DS, Kim HT, Kumar Biswas P, Do M, Kim DH and Cho SG: Efficient
improvement of the proliferation, differentiation, and
anti-arthritic capacity of mesenchymal stem cells by simply
culturing on the immobilized FGF2 derived peptide,
44-ERGVVSIKGV-53. J Adv Res. 62:119–141. 2024. View Article : Google Scholar :
|
|
119
|
Eng L, Azad AK, Habbous S, Pang V, Xu W,
Maitlandvan der Zee AH, Savas S, Mackay HJ, Amir E and Liu G:
Vascular endothelial growth factor pathway polymorphisms as
prognostic and pharmacogenetic factors in cancer: A systematic
review and meta-analysis. Clin Cancer Res. 18:4526–4537. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Michel ZD, Aitken SF, Glover OD, Alejandro
LO, Randazzo D, Dambkowski C, Martin D, Collins MT, Somerman MJ and
Chu EY: Infigratinib, a selective FGFR1-3 tyrosine kinase
inhibitor, alters dentoalveolar development at high doses. Dev Dyn.
252:1428–1448. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Grinspon RP, Castro S, Brunello FG, Sansó
G, Ropelato MG and Rey RA: Diagnosis of male central hypogonadism
during childhood. J Endocr Soc. 5:bvab1452021. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Lu Y, Li B, Zheng X, Xu L, Zeng L, Zhang C
and Zhang J: Discovery and characterization of novel FGFR1 V561M
inhibitors via virtual screening and molecular dynamics
simulations. ACS Med Chem Lett. 16:1575–1584. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Lv M, Shangguan W, Zhao Q, Li Y, Zhao Q
and Li F: Protein kinase B inhibitors enhance the sensitivity of
translocated promoter region-fibroblast growth factor receptor 1
cells to fibroblast growth factor receptor 1 inhibitor-induced
apoptosis. J Int Med Res. 53:30006052513629682025. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Qin S, Sun D, Li H, Li X, Pan W, Yan C,
Tang R and Liu X: The Effect of SHH-Gli signaling pathway on the
synovial fibroblast proliferation in rheumatoid arthritis.
Inflammation. 39:503–512. 2016. View Article : Google Scholar
|
|
125
|
Kschonsak YT, Liang WC, Chan J, Kan D,
Nguyen T, Ruiz K, Kee YS, Tsai WK, Xi H, Moskalenko M, et al:
Tumor-targeted bispecific antibodies effectively inhibit oncogenic
pathways while minimizing toxicity. Sci Adv. 12:eadx39592026.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Compton JT and Lee FY: A review of
osteocyte function and the emerging importance of sclerostin. J
Bone Joint Surg Am. 96:1659–1668. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Chen LC, Shibu MA, Liu CJ, Han CK, Ju DT,
Chen PY, Viswanadha VP, Lai CH, Kuo WW and Huang CY: ERK1/2
mediates the lipopolysaccharide-induced upregulation of FGF-2, uPA,
MMP-2, MMP-9 and cellular migration in cardiac fibroblasts. Chem
Biol Interact. 306:62–69. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Wang K, Ji W, Yu Y, Li Z, Niu X, Xia W and
Lu S: FGFR1-ERK1/2-SOX2 axis promotes cell proliferation,
epithelial-mesenchymal transition, and metastasis in
FGFR1-amplified lung cancer. Oncogene. 37:5340–5354. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
McKenzie J, Smith C, Karuppaiah K,
Langberg J, Silva MJ and Ornitz DM: Osteocyte death and bone
overgrowth in mice lacking fibroblast growth factor receptors 1 and
2 in mature osteoblasts and osteocytes. J Bone Miner Res.
34:1660–1675. 2019. View Article : Google Scholar
|
|
130
|
O'Shea PJ, Guigon CJ, Williams GR and
Cheng SY: Regulation of fibroblast growth factor receptor-1 (FGFR1)
by thyroid hormone: identification of a thyroid hormone response
element in the murine Fgfr1 promoter. Endocrinology. 148:5966–5976.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Florez-Martin M, Radu AM, Shakib K and
Jell G: Osteoblastic cell responses to zoledronate treatment
in-vitro: A systematic review. Bone. 205:1177962026. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Salhotra A, Shah HN, Levi B and Longaker
MT: Mechanisms of bone development and repair. Nat Rev Mol Cell
Biol. 21:696–711. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
White KE, Cabral JM, Davis SI, Fishburn T,
Evans WE, Ichikawa S, Fields J, Yu X, Shaw NJ, McLellan NJ, et al:
Mutations that cause osteoglophonic dysplasia define novel roles
for FGFR1 in bone elongation. Am J Hum Genet. 76:361–367. 2005.
View Article : Google Scholar :
|
|
134
|
Wilkie AO: Bad bones, absent smell,
selfish testes: The pleiotropic consequences of human FGF receptor
mutations. Cytokine Growth Factor Rev. 16:187–203. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Jacob AL, Smith C, Partanen J and Ornitz
DM: Fibroblast growth factor receptor 1 signaling in the
osteo-chondrogenic cell lineage regulates sequential steps of
osteoblast maturation. Dev Biol. 296:315–328. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Maruyama T, Mirando AJ, Deng CX and Hsu W:
The balance of WNT and FGF signaling influences mesenchymal stem
cell fate during skeletal development. Sci Signal. 3:ra402010.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Rice DP, Rice R and Thesleff I: Fgfr mRNA
isoforms in craniofacial bone development. Bone. 33:14–27. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Zhang Y, Su N, Luo F, Wen X, Tang Y, Yang
J, Chen S, Jiang W, Du X and Chen L: Deletion of Fgfr1 in
osteoblasts enhances mobilization of EPCs into peripheral blood in
a mouse endotoxemia model. Int J Biol Sci. 10:1064–1071. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Xiao Z, Huang J, Cao L, Liang Y, Han X and
Quarles LD: Osteocyte-specific deletion of Fgfr1 suppresses FGF23.
PLoS One. 9:e1041542014. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Lee Y, Bae KJ, Chon HJ, Kim SH, Kim SA and
Kim J: A receptor tyrosine kinase inhibitor, dovitinib (TKI-258),
Enhances BMP-2-Induced osteoblast differentiation in vitro. Mol
Cells. 39:389–394. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Wu AL, Feng B, Chen MZ, Kolumam G,
Zavala-Solorio J, Wyatt SK, Gandham VD, Carano RA and Sonoda J:
Antibody-mediated activation of FGFR1 induces FGF23 production and
hypophosphatemia. PLoS One. 8:e573222013. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Chen ZH, Wu JJ, Guo DY, Li YY, Chen MN,
Zhang ZY, Yuan ZD, Zhang KW, Chen WW, Tian F, et al: Physiological
functions of podosomes: From structure and function to therapy
implications in osteoclast biology of bone resorption. Ageing Res
Rev. 85:1018422023. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Chen Z, Encarnacion AM, Rajan RPS, Yao H,
Lee S, Kim E and Lee TH: Discovery of a novel homoisoflavonoid
derivative 5g for anti-osteoclastic bone loss via targeting FGFR1.
Eur J Med Chem. 270:1163352024. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Kawaguchi H, Chikazu D, Nakamura K,
Kumegawa M and Hakeda Y: Direct and indirect actions of fibroblast
growth factor 2 on osteoclastic bone resorption in cultures. J Bone
Miner Res. 15:466–473. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Chikazu D, Hakeda Y, Ogata N, Nemoto K,
Itabashi A, Takato T, Kumegawa M, Nakamura K and Kawaguchi H:
Fibroblast growth factor (FGF)-2 directly stimulates mature
osteoclast function through activation of FGF receptor 1 and
p42/p44 MAP kinase. J Biol Chem. 275:31444–31450. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Nakajima A, Nakajima F, Shimizu S,
Ogasawara A, Wanaka A, Moriya H, Einhorn TA and Yamazaki M: Spatial
and temporal gene expression for fibroblast growth factor type I
receptor (FGFR1) during fracture healing in the rat. Bone.
29:458–466. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Lu X, Su N, Yang J, Huang W, Li C, Zhao L,
He Q, Du X, Shen Y, Chen B and Chen L: Fibroblast growth factor
receptor 1 regulates the differentiation and activation of
osteoclasts through Erk1/2 pathway. Biochem Biophys Res Commun.
390:494–499. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Aukes K, Forsman C, Brady NJ, Astleford K,
Blixt N, Sachdev D, Jensen ED, Mansky KC and Schwertfeger KL:
Breast cancer cell-derived fibroblast growth factors enhance
osteoclast activity and contribute to the formation of metastatic
lesions. PLoS One. 12:e01857362017. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
O'Hagan A, Siefker-Radtke A, Loriot Y,
Deprince K, Crow L, Laron M, Adelman R, Sweiti H and Triantos S:
Incidence and outcomes of FGFR inhibitor-associated retinopathy of
patients treated with oral erdafitinib across the clinical trial
program. Oncologist. 31:oyag1742026. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Zhang Y, Ling L, Ajay D/OAA, Eio YM, van
Wijnen AJ, Nurcombe V and Cool SM: FGFR2 accommodates osteogenic
cell fate determination in human mesenchymal stem cells. Gene.
818:1461992022. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Michigami T: Advances in understanding of
phosphate homeostasis and related disorders. Endocr J. 69:881–896.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Karolak MR, Yang X and Elefteriou F: FGFR1
signaling in hypertrophic chondrocytes is attenuated by the Ras-GAP
neurofibromin during endochondral bone formation. Hum Mol Genet.
24:2552–2564. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Tuzon CT, Rigueur D and Merrill AE:
Nuclear fibroblast growth factor receptor signaling in skeletal
development and disease. Curr Osteoporos Rep. 17:138–146. 2019.
View Article : Google Scholar
|
|
154
|
Wang Z, Huang Y, He Y, Khor S, Zhong X,
Xiao J, Ye Q and Li X: Myocardial protection by heparin-based
coacervate of FGF10. Bioact Mater. 6:1867–1877. 2020.PubMed/NCBI
|
|
155
|
Song H, Du H, Li J, Wang M, Wang J, Ju X
and Mu W: Effect of fibroblast growth factor 2 on degenerative
endplate chondrocyte: From anabolism to catabolism. Exp Mol Pathol.
118:1045902021. View Article : Google Scholar
|
|
156
|
Tang J, Su N, Zhou S, Xie Y, Huang J, Wen
X, Wang Z, Wang Q, Xu W, Du X, et al: Fibroblast growth factor
receptor 3 inhibits osteoarthritis progression in the knee joints
of adult mice. Arthritis Rheumatol. 68:2432–2443. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Weng T, Yi L, Huang J, Luo F, Wen X, Du X,
Chen Q, Deng C, Chen D and Chen L: Genetic inhibition of fibroblast
growth factor receptor 1 in knee cartilage attenuates the
degeneration of articular cartilage in adult mice. Arthritis Rheum.
64:3982–3992. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Shen J, Li J, Wang B, Jin H, Wang M, Zhang
Y, Yang Y, Im HJ, O'Keefe R and Chen D: Deletion of the
transforming growth factor β receptor type II gene in articular
chondrocytes leads to a progressive osteoarthritis-like phenotype
in mice. Arthritis Rheum. 65:3107–3119. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Zhou YX, Xu X, Chen L, Li C, Brodie SG and
Deng CX: A Pro250Arg substitution in mouse Fgfr1 causes increased
expression of Cbfa1 and premature fusion of calvarial sutures. Hum
Mol Genet. 9:2001–2008. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Wang Z, Huang J, Zhou S, Luo F, Tan Q, Sun
X, Ni Z, Chen H, Du X, Xie Y and Chen L: Loss of Fgfr1 in
chondrocytes inhibits osteoarthritis by promoting autophagic
activity in temporomandibular joint. J Biol Chem. 293:8761–8774.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Gao Z, Hou Y, Kong F and Hou S:
Downregulation of microRNA-574-3p expression in human lumbar disc
degeneration and its improvement of degenerative changes in nucleus
pulposus cells via targeting FGFR3. Arch Biochem Biophys.
782:1108462026. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Yao X, Zhang J, Jing X, Ye Y, Guo J, Sun K
and Guo F: Fibroblast growth factor 18 exerts anti-osteoarthritic
effects through PI3K-AKT signaling and mitochondrial fusion and
fission. Pharmacol Res. 139:314–324. 2019. View Article : Google Scholar
|
|
163
|
Delucchi Á, Toro L, Alzamora R, Barrientos
V, González M, Andaur R, León P, Villanueva F, Galindo M, Las Heras
F, et al: Glucocorticoids decrease longitudinal bone growth in
pediatric kidney transplant recipients by stimulating the
FGF23/FGFR3 signaling pathway. J Bone Miner Res. 34:1851–1861.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Davidson D, Blanc A, Filion D, Wang H,
Plut P, Pfeffer G, Buschmann MD and Henderson JE: Fibroblast growth
factor (FGF) 18 signals through FGF receptor 3 to promote
chondrogenesis. J Biol Chem. 280:20509–20515. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Valverde-Franco G, Binette JS, Li W, Wang
H, Chai S, Laflamme F, Tran-Khanh N, Quenneville E, Meijers T,
Poole AR, et al: Defects in articular cartilage metabolism and
early arthritis in fibroblast growth factor receptor 3 deficient
mice. Hum Mol Genet. 15:1783–1792. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Peng Z, Gao L, Zhang L, Yao R, Li X, Deng
L, Fan J, Ying L and Wang Y: Development of FGF21 mutant with
potent cardioprotective effects in T2D Mice via FGFR1-AMPK-Mediated
inhibition of oxidative stress. Int J Mol Sci. 26:65772025.
View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Reed JR, Stone MD, Beadnell TC, Ryu Y,
Griffin TJ and Schwertfeger KL: Fibroblast growth factor receptor 1
activation in mammary tumor cells promotes macrophage recruitment
in a CX3CL1-dependent manner. PLoS One. 7:e458772012. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Zhao YN, Liu ZD, Yan T, Xu TX, Jin TY,
Jiang YS, Zuo W, Lee KY, Huang LJ and Wang Y: Macrophage-specific
FGFR1 deletion alleviates high-fat-diet-induced liver inflammation
by inhibiting the MAPKs/TNF pathways. Acta Pharmacol Sin.
45:988–1001. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Bohrer LR and Schwertfeger KL: Macrophages
promote fibroblast growth factor receptor-driven tumor cell
migration and invasion in a CXCR2-dependent manner. Mol Cancer Res.
10:1294–1305. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Yan M, Yang H, He W, Lei H, Feng N, Guan
W, Feng W and Han L: PZP deficiency impairs M2 macrophage
polarization via TGF-β/Smad3 signaling, contributing to immune
dysregulation at the maternal-fetal interface in preeclampsia. Mol
Immunol. 194:1–12. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Haolan, Wang Y, Gao Y, Liu Y, Deng B, Li
P, Guo J and Sun Z: Esketamine attenuated sepsis-induced organ
injury in mice via the TGF-β-Smad3 signaling pathway. Cytokine.
203:1571632026. View Article : Google Scholar
|
|
172
|
Wu JJ, Sun ZL, Liu SY, Chen ZH, Yuan ZD,
Zou ML, Teng YY, Li YY, Guo DY and Yuan FL: The ASIC3-M-CSF-M2
macrophage-positive feedback loop modulates
fibroblast-to-myofibroblast differentiation in skin fibrosis
pathogenesis. Cell Death Dis. 13:5272022. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Davidson S, Coles M, Thomas T, Kollias G,
Ludewig B, Turley S, Brenner M and Buckley CD: Fibroblasts as
immune regulators in infection, inflammation and cancer. Nat Rev
Immunol. 21:704–717. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Marsh LJ, Kemble S, Reis Nisa P, Singh R
and Croft AP: Fibroblast pathology in inflammatory joint disease.
Immunol Rev. 302:163–183. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Komatsu N and Takayanagi H: Mechanisms of
joint destruction in rheumatoid arthritis - immune
cell-fibroblast-bone interactions. Nat Rev Rheumatol. 18:415–429.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Buckley CD, Ospelt C, Gay S and Midwood
KS: Author correction: Location, location, location: how the tissue
microenvironment affects inflammation in RA. Nat Rev Rheumatol.
17:2462021. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Bartok B and Firestein GS: Fibroblast-like
synoviocytes: key effector cells in rheumatoid arthritis. Immunol
Rev. 233:233–255. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Danks L, Komatsu N, Guerrini MM, Sawa S,
Armaka M, Kollias G, Nakashima T and Takayanagi H: RANKL expressed
on synovial fibroblasts is primarily responsible for bone erosions
during joint inflammation. Ann Rheum Dis. 75:1187–1195. 2016.
View Article : Google Scholar
|
|
179
|
Lang J, Li L, Quan Y, Tan R, Zhao J, Li M,
Zeng J, Chen S, Wang T, Li Y, et al: LC-MS-based metabolomics
reveals the mechanism of anti-gouty arthritis effect of Wuwei
Shexiang pill. Front Pharmacol. 14:12136022023. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Gao X, Zhu X, Lin Y, Liu C, Wang Q and Lin
X: Targeting 5-methylcytosine RNA methylation-mediated
CX26/IκBα/NF-κB signaling by salvianolic acid B attenuates
rheumatoid arthritis progression. Phytomedicine. 157:1583002026.
View Article : Google Scholar
|
|
181
|
Li S, Li F, Xu M, Cheng N, Wan L and Zhang
X: m6A-associated GAS6 expression is associated with
pathogenic activation of fibroblast-like synoviocytes in rheumatoid
arthritis. Sci Rep. May 21–2026.Epub ahead of print.
|
|
182
|
Tang C, Wang Z, Xie Y, Fei Y, Luo J, Wang
C, Ying Y, He P, Yan R, Chen Y, et al: Classification of distinct
tendinopathy subtypes for precision therapeutics. Nat Commun.
15:94602024. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Nygaard G and Firestein GS: Restoring
synovial homeostasis in rheumatoid arthritis by targeting
fibroblast-like synoviocytes. Nat Rev Rheumatol. 16:316–333. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Qiao Z, Meng Q, Xiao B, Long Y, Liang Q
and Su T: Brevilin A, a novel LRRC15 inhibitor, exerts potent
anti-rheumatoid arthritis effects by inhibiting the LRRC15/STAT3
signaling pathway. Arthritis Res Ther. 27:1672025. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Chang CJ, Chang TM, Sun YS, Lin JF, Lee
CW, Fang ML and Liu JF: Lutein attenuates rheumatoid arthritis
progression by suppressing MAPK/NF-κB signaling and MMP3 and MMP13
expression in fibroblast-like Synoviocytes. Int Immunopharmacol.
164:1153602025. View Article : Google Scholar
|
|
186
|
Liu J, Zhang C, Ma R, Yin C, Ren J, Yang
S, Zhao Y, Tang Y, Wei J and Li X: Knockdown of MiD49 and MiD51
alleviates collagen-induced arthritis and suppresses mitophagy and
fatty acid oxidation (FAO) in rheumatoid arthritis fibroblast-like
synoviocytes. Free Radic Biol Med. 240:514–531. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Gao X, Lyu S, Lin T, He J, Pan W, He J,
Wang X, Lin X, Chen J and Wang Q: Oxyimperatorin suppresses the
pathologies of rheumatoid arthritis and the growth of synovial
organoids through targeting the PI3K/AKT Pathway. Phytother Res.
39:3526–3544. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Wang Q, Peng X, Xu H, Zhao Y, Lu X, Lu C,
Wang Q, Lu W, Sheng Q, Lu X, et al: Narirutin mitigates
inflammatory arthritis and osteoporosis through modulating
macrophage phenotype and osteoclastogenesis. J Orthop Translat.
54:115–130. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Wang W, Wang Z, Ling A, Zhang C, Lv M,
Huang L and Niu Y: Research progress in treatment of rheumatoid
arthritis with Sinomenine and related formulations based on
different administration routes. Front Pharmacol. 16:16136792025.
View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Yue S, Fan J, Xie D, Cao C, Wang Z, Huang
J, Qiu F, Yang X, He D, Lu A and Liang C: Unveiling the therapeutic
potential: Targeting fibroblast-like synoviocytes in rheumatoid
arthritis. Expert Rev Mol Med. 27:e182025. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
DeSalvo J, Ban Y, Li L, Sun X, Jiang Z,
Kerr DA, Khanlari M, Boulina M, Capecchi MR, Partanen JM, et al:
ETV4 and ETV5 drive synovial sarcoma through cell cycle and DUX4
embryonic pathway control. J Clin Invest. 131:e1419082021.
View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Shoda J, Tanaka S, Etori K, Hattori K,
Kasuya T, Ikeda K, Maezawa Y, Suto A, Suzuki K, Nakamura J, et al:
Semaphorin 3G exacerbates joint inflammation through the
accumulation and proliferation of macrophages in the synovium.
Arthritis Res Ther. 24:1342022. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Zhao XM, Byrd VM, McKeehan WL, Reich MB,
Miller GG and Thomas JW: Costimulation of human CD4+ T cells by
fibroblast growth factor-1 (acidic fibroblast growth factor). J
Immunol. 155:3904–3911. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Gould PW, Zemel BS, Taratuta EG and Baker
JF: Circulating fibroblast growth factor-21 levels in rheumatoid
arthritis: Associations with disease characteristics, body
composition, and physical functioning. J Rheumatol. 48:504–512.
2021. View Article : Google Scholar
|
|
195
|
Sato H, Kazama JJ, Murasawa A, Otani H,
Abe A, Ito S, Ishikawa H, Nakazono K, Kuroda T, Nakano M and Narita
I: Serum fibroblast growth factor 23 (FGF23) in patients with
rheumatoid arthritis. Intern Med. 55:121–126. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Manabe N, Oda H, Nakamura K, Kuga Y,
Uchida S and Kawaguchi H: Involvement of fibroblast growth factor-2
in joint destruction of rheumatoid arthritis patients. Rheumatology
(Oxford). 38:714–720. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Byrd V, Zhao XM, McKeehan WL, Miller GG
and Thomas JW: Expression and functional expansion of fibroblast
growth factor receptor T cells in rheumatoid synovium and
peripheral blood of patients with rheumatoid arthritis. Arthritis
Rheum. 39:914–922. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Li L, Sun Y, Luo J and Liu M: Circulating
immune cells and risk of osteosarcoma: A Mendelian randomization
analysis. Front Immunol. 15:13812122024. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Balogh E, Biniecka M, Fearon U, Veale DJ
and Szekanecz Z: Angiogenesis in inflammatory arthritis. Isr Med
Assoc J. 21:345–352. 2019.PubMed/NCBI
|
|
200
|
Wang Y, Wu H and Deng R: Angiogenesis as a
potential treatment strategy for rheumatoid arthritis. Eur J
Pharmacol. 910:1745002021. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Leblond A, Allanore Y and Avouac J:
Targeting synovial neoangiogenesis in rheumatoid arthritis.
Autoimmun Rev. 16:594–601. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Zhang YF, Gao SS, Li JL, Zuo WS, Qiu YW
and Xiao YC: Comparison and correlation study of synovial
ultrasound indices and serum VEGF in rheumatoid wrist arthritis
before and after treatment. Clin Rheumatol. 41:2677–2683. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Tan Q, Wang Z, Wang Q, Wang Y, Huang Z, Su
N, Jin M, Kuang L, Qi H, Ni Z, et al: A novel FGFR1-binding peptide
exhibits anti-tumor effect on lung cancer by inhibiting
proliferation and angiogenesis. Int J Biol Sci. 14:1389–1398. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Zhu X, Qiu C, Wang Y, Jiang Y, Chen Y, Fan
L, Ren R, Wang Y, Chen Y, Feng Y, et al: FGFR1 SUMOylation
coordinates endothelial angiogenic signaling in angiogenesis. Proc
Natl Acad Sci USA. 119:e22026311192022. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Lee C, Chen R, Sun G, Liu X, Lin X, He C,
Xing L, Liu L, Jensen LD, Kumar A, et al: VEGF-B prevents excessive
angiogenesis by inhibiting FGF2/FGFR1 pathway. Signal Transduct
Target Ther. 8:3052023. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Wang Y, Wu H, Gui BJ, Liu J, Rong GX, Deng
R, Bu YH and Zhang H: Geniposide alleviates VEGF-induced
angiogenesis by inhibiting VEGFR2/PKC/ERK1/2-mediated SphK1
translocation. Phytomedicine. 100:1540682022. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Luo J, Liang Y, Kong F, Qiu J, Liu X, Chen
A, Luxon BA, Wu HW and Wang Y: Vascular endothelial growth factor
promotes the activation of hepatic stellate cells in chronic
schistosomiasis. Immunol Cell Biol. 95:399–407. 2017. View Article : Google Scholar
|
|
208
|
Wu Q, Han L, Gui W, Wang F, Yan W and
Jiang H: MiR-503 suppresses fibroblast activation and myofibroblast
differentiation by targeting VEGFA and FGFR1 in silica-induced
pulmonary fibrosis. J Cell Mol Med. 24:14339–14348. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Gao M, Li X, Yang M, Feng W, Lin Y and He
T: TNFAIP3 mediates FGFR1 activation-induced breast cancer
angiogenesis by promoting VEGFA expression and secretion. Clin
Transl Oncol. 24:2453–2465. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Oberkersch RE, Pontarin G, Astone M,
Spizzotin M, Arslanbaeva L, Tosi G, Panieri E, Ricciardi S, Allega
MF, Brossa A, et al: Aspartate metabolism in endothelial cells
activates the mTORC1 pathway to initiate translation during
angiogenesis. Dev Cell. 57:1241–1256.e8. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Nourse MB, Rolle MW, Pabon LM and Murry
CE: Selective control of endothelial cell proliferation with a
synthetic dimerizer of FGF receptor-1. Lab Invest. 87:828–835.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Oliva-Ferrusola E, Baus-Domínguez M,
Torres-Lagares D and Serrera-Figallo MA: Genetic aspects of dental
impaction: A scoping review. Genes (Basel). 17:2652026. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Čemažar L, Šlajpah K, Gredelj Šimec N and
Podgornik H: A case report and a literature review of
myeloid/lymphoid neoplasm with eosinophilia and PCM1::JAK2
rearrangement representing as B-cell acute lymphoblastic leukemia
B-ALL. Ann Hematol. 105:52026. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Li D, Yan M, Yang M, Yu Y, Bai X, He Y,
Liu K and Fan H: 20(S)-PPD-HSA NPs enhance the recovery of
intramedullary and extramedullary hematopoiesis in
cyclophosphamide-treated mice through activation of the FGFR1/ERK
pathway. Int Immunopharmacol. 170:1160732026. View Article : Google Scholar
|
|
215
|
Huang Y, Liao J, Shen P, He Y, Sun F,
Zhang Q, Zheng C, Zhang X, Li H and Chen G: Nf2/FGFR1/AKT axis
directs cranial neural crest-derived skull morphogenesis via
collagen synthesis and trafficking. JCI Insight. 10:e1911122025.
View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Zhang X and Xu J: Fibroblast growth factor
23-mediated regulation of osteoporosis: Assessed via Mendelian
randomization and in vitro study. J Cell Mol Med. 28:e185512024.
View Article : Google Scholar
|
|
217
|
Hagan AS, Boylan M, Smith C,
Perez-Santamarina E, Kowalska K, Hung IH, Lewis RM, Hajihosseini
MK, Lewandoski M and Ornitz DM: Generation and validation of novel
conditional flox and inducible Cre alleles targeting fibroblast
growth factor 18 (Fgf18). Dev Dyn. 248:882–893. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Freeman KW, Gangula RD, Welm BE, Ozen M,
Foster BA, Rosen JM, Ittmann M, Greenberg NM and Spencer DM:
Conditional activation of fibroblast growth factor receptor (FGFR)
1, but not FGFR2, in prostate cancer cells leads to increased
osteopontin induction, extracellular signal-regulated kinase
activation, and in vivo proliferation. Cancer Res. 63:6237–6243.
2003.PubMed/NCBI
|
|
219
|
Pendurthi UR, Rao LV, Williams JT and
Idell S: Regulation of tissue factor pathway inhibitor expression
in smooth muscle cells. Blood. 94:579–586. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Pond AC, Herschkowitz JI, Schwertfeger KL,
Welm B, Zhang Y, York B, Cardiff RD, Hilsenbeck S, Perou CM,
Creighton CJ, et al: Fibroblast growth factor receptor signaling
dramatically accelerates tumorigenesis and enhances oncoprotein
translation in the mouse mammary tumor virus-Wnt-1 mouse model of
breast cancer. Cancer Res. 70:4868–4879. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Stubbs JR, He N, Idiculla A, Gillihan R,
Liu S, David V, Hong Y and Quarles LD: Longitudinal evaluation of
FGF23 changes and mineral metabolism abnormalities in a mouse model
of chronic kidney disease. J Bone Miner Res. 27:38–46. 2012.
View Article : Google Scholar
|
|
222
|
Yuan B, Feng JQ, Bowman S, Liu Y, Blank
RD, Lindberg I and Drezner MK: Hexa-D-arginine treatment increases
7B2•PC2 activity in hyp-mouse osteoblasts and rescues the HYP
phenotype. J Bone Miner Res. 28:56–72. 2013. View Article : Google Scholar
|
|
223
|
Smolen JS, Landewé RBM, Bergstra SA,
Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards CJ,
Hyrich KL, Pope JE, et al: EULAR recommendations for the management
of rheumatoid arthritis with synthetic and biological
disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis.
82:3–18. 2023. View Article : Google Scholar
|
|
224
|
Firestein GS and McInnes IB:
Immunopathogenesis of rheumatoid arthritis. Immunity. 46:183–196.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Karabhari A, Rathee S, Soni S and Patil
UK: Rheumatoid arthritis: A comprehensive review of etiology,
pathophysiology, and innovative therapeutic advancements. Curr
Pharm Des. May 8–2026.Epub ahead of print. View Article : Google Scholar
|
|
226
|
Cruciani G, Cafaro G, Perricone C, Dal
Pozzolo R, Bruno L, Tromby F, Colangelo A, Gerli R and Bartoloni E:
Sequential treatment strategies following methotrexate inadequate
response in rheumatoid arthritis: A real-world retrospective cohort
study. Clin Exp Rheumatol. May 13–2026.Epub ahead of print.
View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Chen Y, Zhou YF, Long ZY, Peng YM, Wu SX,
Peng F, Yuan MH, Zhou YZ, Wang L and Yuan H: Therapeutic potential
of spermidine in rheumatoid arthritis: Mechanisms and future
directions. Int J Rheum Dis. 29:e706102026. View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Leiva-Escobar I, Chennas AP, Alayash Z,
Reckelkamm SL, Holtfreter B, Kocher T, Baumeister SE and Nolde M:
Nonsteroidal anti-inflammatory drugs and the risk of periodontitis
among adults with osteoarthritis: A target trial emulation. J Clin
Periodontol. May 23–2026.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Konzett V, Laskou F, Smolen JS, Edwards
CJ, Aletaha D, van der Heijde D, Winthrop KL, Takeuchi T, Caporali
R, Verschueren P, et al: Efficacy of synthetic and biological
DMARDs: A systematic literature review informing the 2025 update of
the EULAR recommendations for the management of rheumatoid
arthritis. Ann Rheum Dis. 85:1039–1054. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
230
|
Ellis H, Balasooriya ER, Varkaris A,
Hajian B, Wan J, Shekhar M, Gritti I, Vijay V, Albertelli L, Piot
S, et al: Mechanisms of clinical resistance to selective FGFR2
inhibition by lirafugratinib. Ann Oncol. 37:798–812. 2026.
View Article : Google Scholar : PubMed/NCBI
|
|
231
|
Suzuki R, Watanabe S, Shono K, Masuda T,
Yanai K, Yamazaki R, Ando Y, Wakabayashi T, Tanaka S, Sekiya T, et
al: Nintedanib enhances the antitumor efficacy of pd-1 blockade,
potentially through inhibition of myeloid-derived suppressor cells
and cancer-associated fibroblasts. Cancer Immunol Immunother.
75:942026. View Article : Google Scholar : PubMed/NCBI
|
|
232
|
Boggavarapu RK and Chimakurthy J:
Preclinical pharmacokinetics of erdafitinib, an FGFR tyrosine
kinase inhibitor, via LC-MS/MS in sprague dawley rats. Rapid Commun
Mass Spectrom. 40:e701162026. View Article : Google Scholar : PubMed/NCBI
|
|
233
|
Pirvola U, Ylikoski J, Trokovic R, Hébert
JM, McConnell SK and Partanen J: FGFR1 is required for the
development of the auditory sensory epithelium. Neuron. 35:671–680.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
234
|
Wang C, Chang JY, Yang C, Huang Y, Liu J,
You P, McKeehan WL, Wang F and Li X: Type 1 fibroblast growth
factor receptor in cranial neural crest cell-derived mesenchyme is
required for palatogenesis. J Biol Chem. 288:22174–22183. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
235
|
Kawai M, Herrmann D, Fuchs A, Cheng S,
Ferrer-Vaquer A, Götz R, Driller K, Neubüser A and Ohura K: Fgfr1
conditional-knockout in neural crest cells induces heterotopic
chondrogenesis and osteogenesis in mouse frontal bones. Med Mol
Morphol. 52:156–163. 2019. View Article : Google Scholar
|
|
236
|
Takamori K, Hosokawa R, Xu X, Deng X,
Bringas P Jr and Chai Y: Epithelial fibroblast growth factor
receptor 1 regulates enamel formation. J Dent Res. 87:238–243.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
237
|
Pei F, Ma L, Guo T, Zhang M, Jing J, Wen
Q, Feng J, Lei J, He J, Janečková E, et al: Sensory nerve regulates
progenitor cells via FGF-SHH axis in tooth root morphogenesis.
Development. 151:dev2020432024. View Article : Google Scholar
|
|
238
|
Maniou E, Farah F, Marshall AR,
Crane-Smith Z, Krstevski A, Stathopoulou A, Greene NDE, Copp AJ and
Galea GL: Caudal Fgfr1 disruption produces localised spinal
mis-patterning and a terminal myelocystocele-like phenotype in
mice. Development. 150:dev2021392023. View Article : Google Scholar : PubMed/NCBI
|
|
239
|
Siefker-Radtke AO, Necchi A, Park SH,
García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh
Kalebasty A, Mellado B, Varlamov S, et al: Efficacy and safety of
erdafitinib in patients with locally advanced or metastatic
urothelial carcinoma: Long-term follow-up of a phase 2 study.
Lancet Oncol. 23:248–258. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
240
|
CADTH Reimbursement Reviews and
Recommendations: Pemigatinib (Pemazyre): Indication: For the
treatment of adults with previously treated, unresectable locally
advanced or metastatic Cholangiocarcinoma with a FGFR2 fusion or
other rearrangement: Reimbursement Recommendation. Canadian Agency
for Drugs and Technologies in Health; Ottawa, ON: 2025
|
|
241
|
Li P, Wu L and Song Z: Data mining and
safety analysis of FGFR tyrosine kinase inhibitors based on the
FAERS database. Sci Rep. 15:261502025. View Article : Google Scholar : PubMed/NCBI
|
|
242
|
Sasanuma H and Yamaguchi H: Sequential
fibroblast growth factor receptor inhibition in intrahepatic
cholangiocarcinoma: Navigating an evolving landscape of resistance
and opportunity-A case report and current opinion. Oncol Ther.
13:1243–1253. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
243
|
Adashek JJ, Kato S, Sicklick JK, Lippman
SM and Kurzrock R: If it's a target, it's a pan-cancer target:
Tissue is not the issue. Cancer Treat Rev. 125:1027212024.
View Article : Google Scholar : PubMed/NCBI
|
|
244
|
Thein KZ, Myat YM, Park BS, Panigrahi K
and Kummar S: Target-driven tissue-agnostic drug approvals-A new
path of drug development. Cancers (Basel). 16:25292024. View Article : Google Scholar : PubMed/NCBI
|
|
245
|
Newbold K and Cheng L: Targeting RET in
medullary thyroid cancer. Endocr Relat Cancer. 32:e2402912025.
View Article : Google Scholar : PubMed/NCBI
|
|
246
|
Meertens M, de Jong LD, de Vries N, Rosing
H, Beijnen JH and Huitema ADR: LC-MS/MS method development and
validation for novel targeted anticancer therapies adagrasib,
capmatinib, ensartinib, entrectinib, larotrectinib, lorlatinib,
pralsetinib, selpercatinib and sotorasib. J Pharm Biomed Anal.
266:1170782025. View Article : Google Scholar : PubMed/NCBI
|
|
247
|
Seguchi K, Enokida T, Oba T, Yoshikawa AL,
Nakatake N and Yu O: A case of micro-medullary thyroid carcinoma
presenting as cancer of unknown primary. Cureus.
17:e870852025.PubMed/NCBI
|
